After decades of unfulfilled potential, the commercial reality of gene therapies is rapidly taking shape. However, the leading drug developer organizations in this field are telling us that developing effective analytical strategies is a major bottleneck for them and that they have little visibility into which contract service providers and technology providers have the analytical experience and specific technologies to meet their demands.
150+ Analytical, CMC, Process Development & QC leaders from the fields leading companies will virtually unite in May at the 2nd Annual Gene Therapy Analytical Development Europe. From extensive research with these organisations, we are aware that they are all actively seeking to collaborate with companies that can help them solve their analytical challenges holding back progress to market.
If you are a contract service or technology provider with the analytical experience and specific technologies to meet this exploding markets’ demands, then Gene Therapy Analytical Development Europe will provide an online platform for you to showcase your solutions to a niche audience of analytical experts from the leading gene therapy developers.
We have a limited number of partnership opportunities available, including virtual speaking positions across our agenda. From developing robust potency assays to next-generation sequencing, if you provide analytical services or technologies that would benefit our niche industry audience, then this meeting will provide a unique platform to showcase your solutions, generate new business leads, and source opportunities for partnerships.
Showcase your expertise to leading organisations by securing a virtual exhibition booth
Secure a spot on our expert speaker faculty to demonstrate thought leadership and drive brand exposure
Maximise the balance of 2:1 live content and targeted online networking to generate leads and build new relationships with gene therapy pioneers
Embrace the tech to meet your 2020 commercial objectives and educate decision-makers on how your expertise can deliver gene therapies to patients more effectively